Program
relatlimab
Also written as “Relatlimab”, “Nivolumab + Relatlimab” and “relatlimab+nivolumab”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Stomach Neoplasms · Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.
Drug pageRelatlimab: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 195 open or running | phase 4since Mar 5, 2026 | Sep 25, 2013 | May 26, 2029phase 4 · NCT07459543 |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics and Ono Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Sep 25, 2013.
- Dec 15, 2016Phase 2 study in Advanced CancerNCT02996110 · 182 enrolled · United States, Australia, Austria and more
- Nov 6, 2017Phase 1 study in Advanced CancerNCT03335540 · 20 enrolled · United States
- Jun 9, 2018Named relatlimabINNProposed as its International Nonproprietary Name in WHO's List 119
- Oct 9, 2018Phase 2 study in Stomach NeoplasmsNCT03704077 · United States, Argentina, Australia and more
- Apr 1, 2019Phase 2 study in NeoplasmsNCT03899155 · 1,500 planned · United States, Argentina, Australia and more
- Jun 5, 2019Phase 1 study in MelanomaNCT03978611 · 11 enrolled · United States, Belgium, Canada and more
- Nov 5, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04623775 · 468 enrolled · United States, Argentina, Australia and more
- Aug 4, 2021Phase 3 study in MelanomaNCT05002569 · 1,093 enrolled · United States, Argentina, Australia and more
- Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
- Apr 13, 2022Phase 2 study in Carcinoma, HepatocellularNCT05337137 · 82 enrolled · United States, Australia, Canada and more
- Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
- Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
- Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
- Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India
Ahead
- May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
- Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
- Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386
TargetBeta
“A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule
Other programs on LAG3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fianlimabrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| Anti-PD-1/LAG-3 Bispecific Antibody AK129rule | Akeso | phase 2 | 4 |
| TQB2252 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459543Melanoma · India | 4 | Not yet recruiting | May 26, 2029 | 40 |
| NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jul 30, 2030 | 1,000 |
| NCT06101134Melanoma · United States, Chile, Greece and more | 2 | Active, not recruiting | Apr 10, 2025 | 100 |
| NCT05625399Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 4, 2025 | 579 |
| NCT05498480Advanced Solid Tumors · China | 1 | Completed | Jan 18, 2024 | 6 |
| NCT05337137Carcinoma, Hepatocellular · United States, Australia, Canada and more | 2 | Completed | Jul 5, 2025 | 82 |
| NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more | 2 | Terminated | Dec 3, 2025 | 5 |
| NCT05002569Melanoma · United States, Argentina, Australia and more | 3 | Terminated | Dec 16, 2024 | 1,093 |
| NCT04623775Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Completed | Jan 11, 2024 | 468 |
| NCT03978611Melanoma · United States, Belgium, Canada and more | 1 | Terminated | Jul 26, 2023 | 11 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Aug 25, 2029 | 1,500 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Feb 27, 2022 | 0 |
| NCT03335540Advanced Cancer · United States | 1 | Completed | Mar 31, 2021 | 20 |
| NCT02996110Advanced Cancer · United States, Australia, Austria and more | 2 | Completed | Nov 23, 2021 | 182 |
| NCT02966548Neoplasms · Japan | 1 | Completed | Jul 9, 2024 | 35 |
| NCT02935634Advanced Gastric Cancer · United States, Australia, Canada and more | 2 | Completed | May 11, 2022 | 190 |
| NCT02750514Advanced Cancer · United States, Australia, Austria and more | 2 | Terminated | Jan 29, 2020 | 295 |
| NCT02061761Hematologic Neoplasms · United States, Canada | 2 | Completed | Feb 16, 2022 | 106 |
| NCT01968109Neoplasms by Site · United States, Australia, Austria and more | 2 | Completed | May 22, 2024 | 1,482 |
How it is read
Names in the registry
- “Relatlimab”, 13 entries
- “Nivolumab + Relatlimab”, 3 entries
- “relatlimab+nivolumab”, 1 entry
- “relatlimab+nivolumab+rHuPH20”, 1 entry
- “Nivolumab + Relatlimab Fixed Dose Combination”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 5 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Neoplasms, 2 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.